SCHEDULE 13G: State Street Corporation Discloses 5.2% Passive Stake in Ironwood Pharmaceuticals
Beneficial Ownership Report (Schedule 13G)
State Street Corporation has filed a Schedule 13G, reporting a passive beneficial ownership of 5.2% in Ironwood Pharmaceuticals Inc. as of December 31, 2024.
Summary
- State Street Corporation, a Massachusetts-based parent holding company, has filed a Schedule 13G with the SEC.
- The filing discloses State Street's beneficial ownership in Ironwood Pharmaceuticals Inc. (CUSIP: 46333X108) common stock.
- As of December 31, 2024, State Street Corporation beneficially owns 8,328,817 shares of Ironwood Pharmaceuticals, representing 5.2% of the class.
- The ownership is primarily held with shared voting power over 7,747,363 shares and shared dispositive power over all 8,328,817 shares.
- The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Ironwood Pharmaceuticals Inc.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, indicating a passive investment. It does not contain information that would inherently suggest a positive or negative sentiment regarding the issuer's performance or outlook.
Future Outlook
NA
Industry Context
This Schedule 13G filing indicates a significant, passive investment by a major institutional asset manager, State Street Corporation, in a pharmaceutical company. Such filings are routine disclosures for large investment firms that cross a 5% ownership threshold, reflecting portfolio management activities rather than strategic corporate actions related to the issuer's operations.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's passive stake, which may offer some stability or confidence in the stock's institutional backing.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires the filing of this statement (beneficial ownership stake established) |
| 01/31/2025 | Date of signature for the Schedule 13G filing |
Keywords
State Street Corporation, Ironwood Pharmaceuticals, Schedule 13G, Beneficial Ownership, Passive Investment, Institutional Investor, Common Stock, SEC Filing, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.